Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 11/20 | 0.64 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.58 |
| ▸ | SELP | P16109 | 2/20 | 0.54 |
| ▸ | SELL | P14151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8673965 | 0.94 | MAG (0.62) | MAGSIGLEC7SELPSELL | |
| SCHEMBL21318889 | 0.94 | MAG (0.62) | MAGSIGLEC7SELPSELL | |
| SCHEMBL21318923 | 0.94 | MAG (0.62) | MAGSIGLEC7SELPSELL | |
| SCHEMBL27420908 | 0.91 | MAG (0.64) | MAGSIGLEC7SELPSELL | |
| SCHEMBL29358356 | 0.90 | MAG (0.64) | MAGSIGLEC7SELPSELL | |
| SCHEMBL29809799 | 0.89 | SIGLEC7 (0.63) | MAGSIGLEC7SELPSELL | |
| SCHEMBL29790139 | 0.89 | SIGLEC7 (0.63) | MAGSIGLEC7SELPSELL | |
| SCHEMBL29376477 | 0.87 | MAG (0.56) | MAGSIGLEC7SELPSELL | |
| SCHEMBL29395515 | 0.87 | MAG (0.61) | MAGSIGLEC7SELPSELL | |
| SCHEMBL30206509 | 0.86 | MAG (0.70) | MAGSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4742899-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742901-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743567-A1 | CELLULAR PRODUCTION OF LACTO-N-TRIOSE (LN3)-CONTAINING OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742900-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742902-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| CN-122029274-A | Cell production of oligosaccharides comprising lacto-N-trisaccharide (LN 3) | 因比奥斯公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12600997-B2 | Fermentative production of sialylated saccharides | CHR. HANSEN A/S (DK) | 2026-04-14 | — | — | US | disclosed |
| EP-4704597-A1 | METHOD TO REDUCE FEED CONVERSION RATIO IN A FARMED ANIMAL | Inbiose N.V. (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704599-A1 | FUCOSYLATED MAMMALIAN MILK OLIGOSACCHARIDE FOR USE IN THE PREVENTION OR TREATMENT OF SHIPPING FEVER | Inbiose N.V. (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704598-A1 | FUCOSYLATED MAMMALIAN MILK OLIGOSACCHARIDE FOR USE IN THE PREVENTION OR TREATMENT OF PNEUMONIA | Inbiose N.V. (BE) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024052405-A1 | ENCAPSULATED MILK SACCHARIDES | INBIOSE N.V. (BE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052406-A1 | BAKED NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024017987-A1 | PRODUCTION OF OLIGOSACCHARIDES IN HOST CELLS | INBIOSE N.V. (BE) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023102364-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-06-08 | — | — | WO | disclosed |
| US-11656224-B2 | Multivalent glycan microarray platform | Z BIOTECH LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230068960-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES | PROLACTA BIOSCIENCE, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3575404-B1 | FERMENTATIVE PRODUCTION OF SIALYLATED SACCHARIDES | CHR HANSEN HMO GMBH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-4034143-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES | Prolacta Bioscience, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220145342-A1 | FERMENTATIVE PRODUCTION OF CARBOHYDRATES BY MICROBIAL CELLS UTILIZING A MIXED FEEDSTOCK | CHR. HANSEN A/S (DK) | 2022-05-12 | — | — | US | disclosed |
| US-20220099666-A1 | MULTIVALENT GLYCAN MICROARRAY PLATFORM | Z BIOTECH, LLC (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600997-B2 | Fermentative production of sialylated saccharides | RNGTT, NANS, ENGASE | MAG 1383/4885SIGLEC7 250/4885SELP 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.